|
|
|
|
|||||
|
|
|
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
[email protected]
| May-28 | |
| May-27 | |
| May-26 | |
| May-16 | |
| May-15 | |
| May-14 | |
| May-09 | |
| May-09 | |
| May-08 | |
| May-08 | |
| May-08 | |
| May-06 | |
| May-06 | |
| May-06 | |
| May-05 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite